RGD peptide-conjugated selenium nanoparticles: Antiangiogenesis by suppressing VEGF-VEGFR2-ERK/AKT pathway

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 6, 2016, Pages 1627-1639

  Fu, Xiaoyan ^a   Yang, Yahui ^a   Li, Xiaoling ^a   Lai, Haoqiang ^a   Huang, Yanyu ^a   He, Lizhen ^a   Zheng, Wenjie ^a   Chen, Tianfeng ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Selenium nanoparticels; Targeted nanodrug delivery; VEGF

Indexed keywords

CARDIOVASCULAR SYSTEM; CELL DEATH; DRUG PRODUCTS; ENDOTHELIAL CELLS; MOLECULAR BIOLOGY; NANOPARTICLES; PEPTIDES; SELENIUM; SYNTHESIS (CHEMICAL); TUMORS;

ANGIOGENESIS; ANTI-ANGIOGENIC ACTIVITY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; NANOPARTICELS; RECEPTOR-MEDIATED ENDOCYTOSIS; SELENIUM NANOPARTICLES; TARGETED NANODRUG DELIVERY; VEGF;

CELL SIGNALING;

ANGIOGENESIS INHIBITOR; ARGINYLGLYCYLASPARTIC ACID; ASPARTATE AMINOTRANSFERASE; CASPASE 3; CASPASE 8; CASPASE 9; CREATINE KINASE; CREATININE; DOXORUBICIN; DRUG CARRIER; LACTATE DEHYDROGENASE; LYSOZYME; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SELENIUM NANOPARTICLE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; NANOPARTICLE; SELENIUM; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL LYSATE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CIRCULATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DNA DAMAGE; DRUG CLEARANCE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RELEASE; ENDOCYTOSIS; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; MCF 7 CELL LINE; MOUSE; NONHUMAN; PLASMA CLEARANCE; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; METABOLISM; NEOPLASMS; NUDE MOUSE;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SELENIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84965060403     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.01.012     Document Type: Article

References (60)

1. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
2. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011, 17:1359-1370.
3. Kowanetz M., Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006, 12:5018-5022.
4. Weis S.M., Cheresh D.A. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005, 437:497-504.
5. Kirsch M., Schackert G., Black P.M. Anti-angiogenic treatment strategies for malignant brain tumors. J Neurooncol 2000, 50:149-163.
6. Zhu Z., Witte L. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs 1999, 17:195-212.
7. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002, 296:2404-2407.
8. Patan S. Vasculogenesis and angiogenesis. Cancer Treat Res 2004, 117:3-32.
9. Cheng S.Y., Huang H.J., Nagane M., Ji X.D., Wang D., Shih C.C., et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1996, 93:8502-8507.
10. Brown L.F., Berse B., Jackman R.W., Tognazzi K., Guidi A.J., Dvorak H.F., et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995, 26:86-91.
11. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
12. Skobe M., Rockwell P., Goldstein N., Vosseler S., Fusenig N.E. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997, 3:1222-1227.
13. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6:273-286.
14. Kerbel R.S. Tumor angiogenesis. N Engl J Med 2008, 358:2039-2049.
15. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996, 12:697-715.
16. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
17. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
18. Sipkins D.A., Cheresh D.A., Kazemi M.R., Nevin L.M., Bednarski M.D., Li K.C. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 1998, 4:623-626.
19. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279:377-380.
20. Wickham T.J. Ligand-directed targeting of genes to the site of disease. Nat Med 2003, 9:135-139.
21. Shi M., Ho K., Keating A., Shoichet M.S. Doxorubicin-Conjugated Immuno-Nanoparticles for Intracellular Anticancer Drug Delivery. Adv Funct Mater 2009, 19:1689-1696.
22. Koo H., Lee S., Na J.H., Kim S.H., Hahn S.K., Choi K., et al. Bioorthogonal copper-free click chemistry in vivo for tumor-targeted delivery of nanoparticles. Angew Chem Int Ed Engl 2012, 51:11836-11840.
23. Sharma S., Chockalingam S., Sanpui P., Chattopadhyay A., Ghosh S.S. Silver nanoparticles impregnated alginate-chitosan-blended nanocarrier induces apoptosis in human glioblastoma cells. Adv Healthc Mater 2014, 3:106-114.
24. Bruchez M.J., Moronne M., Gin P., Weiss S., Alivisatos A.P. Semiconductor nanocrystals as fluorescent biological labels. Science 1998, 281:2013-2016.
25. Tkachenko A.G., Xie H., Coleman D., Glomm W., Ryan J., Anderson M.F., et al. Multifunctional gold nanoparticle-peptide complexes for nuclear targeting. J Am Chem Soc 2003, 125:4700-4701.
26. Fernandes A.P., Gandin V. Selenium compounds as therapeutic agents in cancer. Biochim Biophys Acta 1850, 2015:1642-1660.
27. Saghiri M.A., Asatourian A., Orangi J., Sorenson C.M., Sheibani N. Functional role of inorganic trace elements in angiogenesis-Part I: N, Fe, Se, P, Au, and Ca. Crit Rev Oncol Hematol 2015, 96:129-142.
28. Liu Y., Li W., Guo M., Li C., Qiu C. Protective Role of Selenium Compounds on the Proliferation, Apoptosis, and Angiogenesis of a Canine Breast Cancer Cell Line. Biol Trace Elem Res 2015, 1-8.
29. Gurunathan S., Lee K.J., Kalishwaralal K., Sheikpranbabu S., Vaidyanathan R., Eom S.H. Antiangiogenic properties of silver nanoparticles. Biomaterials 2009, 30:6341-6350.
30. Liu W., Li X.L., Wong Y.S., Zheng W.J., Zhang Y.B., Cao W.Q., et al. Selenium Nanoparticles as a Carrier of 5-Fluorouracil to Achieve Anticancer Synergism. ACS Nano 2012, 6:6578-6591.
31. Vekariya K.K., Kaur J., Tikoo K. ER alpha signaling imparts chemotherapeutic selectivity to selenium nanoparticles in breast cancer. Nanomedicine 2012, 8:1125-1132.
32. Kong L., Yuan Q., Zhu H., Li Y., Guo Q., Wang Q., et al. The suppression of prostate LNCaP cancer cells growth by Selenium nanoparticles through Akt/Mdm2/AR controlled apoptosis. Biomaterials 2011, 32:6515-6522.
33. Yu B., Zhang Y.B., Zheng W.J., Fan C.D., Chen T.F. Positive Surface Charge Enhances Selective Cellular Uptake and Anticancer Efficacy of Selenium Nanoparticles. Inorg Chem 2012, 51:8956-8963.
34. Zhang Y.B., Li X.L., Huang Z., Zheng W.J., Fan C.D., Chen T.F. Enhancement of cell permeabilization apoptosis-inducing activity of selenium nanoparticles by ATP surface decoration. Nanomedicine 2013, 9:74-84.
35. Chen T., Wong Y.S., Zheng W., Bai Y., Huang L. Selenium nanoparticles fabricated in Undaria pinnatifida polysaccharide solutions induce mitochondria-mediated apoptosis in A375 human melanoma cells. Colloids Surf B 2008, 67:26-31.
36. Wang H.L., Zhang J.S., Yu H.Q. Elemental selenium at nano size possesses lower toxicity without compromising the fundamental effect on selenoenzymes: Comparison with selenomethionine in mice. Free Radic Biol Med 2007, 42:1524-1533.
37. Weekley C.M., Aitken J.B., Musgrave I.F., Harris H.H. Methylselenocysteine Treatment Leads to Diselenide Formation in Human Cancer Cells: Evidence from X-ray Absorption Spectroscopy Studies. Biochemistry 2012, 51:736-738.
38. He L., Chen T., You Y., Hu H., Zheng W., Kwong W.L., et al. A cancer-targeted nanosystem for delivery of gold(III) complexes: enhanced selectivity and apoptosis-inducing efficacy of a gold(III) porphyrin complex. Angew Chem Int Ed Engl 2014, 53:12532-12536.
39. Lai H., Zhao Z., Li L., Zheng W., Chen T. Antiangiogenic ruthenium(ii) benzimidazole complexes, structure-based activation of distinct signaling pathways. Metallomics 2015, 7:439-447.
40. Sun H.L., Tsai A.C., Pan S.L., Ding Q.Q., Yamaguchi H., Lin C.N., et al. EPOX Inhibits Angiogenesis by Degradation of Mcl-1 through ERK Inactivation. Clin Cancer Res 2009, 15:4904-4914.
41. Zeng L., Chen J., Ji S., Chan L., Zheng W., Chen T. Construction of a cancer-targeted nanosystem as a payload of iron complexes to reverse cancer multidrug resistance. J Mater Chem B 2015, 3:4345-4354.
42. Liu T., Zeng L., Jiang W., Fu Y., Zheng W., Chen T. Rational design of cancer-targeted selenium nanoparticles to antagonize multidrug resistance in cancer cells. Nanomedicine 2015, 11:947-958.
43. Jiang W., Fu Y., Yang F., Yang Y., Liu T., Zheng W., et al. Gracilaria lemaneiformis polysaccharide as integrin-targeting surface decorator of selenium nanoparticles to achieve enhanced anticancer efficacy. ACS Appl Mater Interfaces 2014, 6:13738-13748.
44. Huang Y.Y., He L.Z., Liu W., Fan C.D., Zheng W.J., Wong Y.S., et al. Selective cellular uptake and induction of apoptosis of cancer-targeted selenium nanoparticles. Biomaterials 2013, 34:7106-7116.
45. Peer D., Karp J.M., Hong S., FaroKHzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
46. Li Y.H., Li X.L., Wong Y.S., Chen T.F., Zhang H.B., Liu C.R., et al. The reversal of cisplatin-induced nephrotoxicity by selenium nanoparticles functionalized with 11-mercapto-1-undecanol by inhibition of ROS-mediated apoptosis. Biomaterials 2011, 32:9068-9076.
47. Wang F., Wang Y.C., Dou S., Xiong M.H., Sun T.M., Wang J. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 2011, 5:3679-3692.
48. Chen F., Zhu Y.C. Chitosan enclosed mesoporous silica nanoparticles as drug nano-carriers: Sensitive response to the narrow pH range. Microporous Mesoporous Mater 2012, 150:83-89.
49. Liu H., Wang C.Y., Zou S.W., Wei Z.J., Tong Z. Simple, Reversible Emulsion System Switched by pH on the Basis of Chitosan without Any Hydrophobic Modification. Langmuir 2012, 28:11017-11024.
50. Palchaudhuri R., Hergenrother P.J. DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action. Curr Opin Biotechnol 2007, 18:497-503.
51. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2:795-803.
52. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8:579-591.
53. Xiao D., Singh S.V. Phenethyl isothiocyanate inhibits angiogenesis in vitro and ex vivo. Cancer Res 2007, 67:2239-2246.
54. Xiao D., Singh S.V. z-Guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, inhibits angiogenesis in vitro and in vivo. Mol Cancer Ther 2008, 7:171-180.
55. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006, 7:359-371.
56. Dai J., Peng L., Fan K., Wang H., Wei R., Ji G., et al. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene 2009, 28:3412-3422.
57. Hirn S., Semmler-Behnke M., Schleh C., Wenk A., Lipka J., Schaffler M., et al. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm 2011, 77:407-416.
58. Jin H.H., Sharma D.A., Strano M.S. Size-Dependent Cellular Uptake and Expulsion of Single-Walled Carbon Nanotubes: Single Particle Tracking and a Generic Uptake Model for Nanoparticles. ACS Nano 2009, 3:149-158.
59. He L., Huang Y., Zhu H., Pang G., Zheng W., Wong Y.-S., et al. Cancer-Targeted Monodisperse Mesoporous Silica Nanoparticles as Carrier of Ruthenium Polypyridyl Complexes to Enhance Theranostic Effects. Adv Funct Mater 2014, 24:2754-2763.
60. Loeschner K., Hadrup N., Hansen M., Pereira S.A., Gammelgaard B., Moller L.H., et al. Absorption, distribution, metabolism and excretion of selenium following oral administration of elemental selenium nanoparticles or selenite in rats. Metallomics 2014, 6:330-337.